NeuroSense Therapeutics Ltd. Research And Development Expense
NeuroSense Therapeutics Ltd. (NRSN) reported Research And Development Expense of $4.00 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-08-16.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2023-08-16
| Period end | Research And Development Expense 6 month | Research And Development Expense 12 month |
|---|---|---|
| 2023-06-30 | $4.00M 6-K · filed 2023-08-16 | |
| 2022-12-31 | $6.42M 6-K · filed 2023-08-16 | |
| 2022-06-30 | $3.17M 6-K · filed 2023-08-16 | |
| 2021-12-31 | $3.08M 6-K/A · filed 2023-01-19 | |
| 2021-06-30 | $2.52M 6-K/A · filed 2023-01-19 |